Reverse Genetics and Artificial Replication Systems of Borna Disease Virus 1

Viruses. 2022 Oct 12;14(10):2236. doi: 10.3390/v14102236.

Abstract

Borna disease virus 1 (BoDV-1) is a neurotropic RNA virus belonging to the family Bornaviridae within the order Mononegavirales. Whereas BoDV-1 causes neurological and behavioral disorders, called Borna disease (BD), in a wide range of mammals, its virulence in humans has been debated for several decades. However, a series of case reports in recent years have established the nature of BoDV-1 as a zoonotic pathogen that causes fatal encephalitis in humans. Although many virological properties of BoDV-1 have been revealed to date, the mechanism by which it causes fatal encephalitis in humans remains unclear. In addition, there are no effective vaccines or antiviral drugs that can be used in clinical practice. A reverse genetics approach to generating replication-competent recombinant viruses from full-length cDNA clones is a powerful tool that can be used to not only understand viral properties but also to develop vaccines and antiviral drugs. The rescue of recombinant BoDV-1 (rBoDV-1) was first reported in 2005. However, due to the slow nature of the replication of this virus, the rescue of high-titer rBoDV-1 required several months, limiting the use of this system. This review summarizes the history of the reverse genetics and artificial replication systems for orthobornaviruses and explores the recent progress in efforts to rescue rBoDV-1.

Keywords: Borna disease virus; orthobornaviruses; reverse genetics; viral replication and transcription.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antiviral Agents / pharmacology
  • Borna disease virus* / genetics
  • DNA, Complementary
  • Encephalitis*
  • Humans
  • Mammals
  • Reverse Genetics
  • Virus Replication / genetics

Substances

  • DNA, Complementary
  • Antiviral Agents

Grants and funding

This research was funded by JSPS KAKENHI, grants JP19J23468 (T.K.), JP19K22530 (K.T.), JP20H05682 (K.T.) and JP21K19909 (K.T.); JST START Project Promotion Type (commercialization support), grant number JPMJST2113 (K.T.); JSPS Core-to-Core Program, JPJSCCA20190008 (K.T.); the 2021 Kaketsuken Research grant (K.T.); and the Joint Usage/Research Center Program of the Institute for Life and Medical Sciences, Kyoto University.